PhRMA's lawsuit argues CMS overstepped its demonstration authority by tying Medicare Part B rebates to international prices.
News|Articles|September 21, 2026
FAQ: How the GENEROUS Model Applies MFN Pricing to Medicaid
Author(s)Stephen Appezzato
CMS says 40 states and Puerto Rico have signed on to the GENEROUS Model, which applies MFN pricing to Medicaid drugs through state-invoiced rebates.
Advertisement
Advertisement
The Centers for Medicare & Medicaid Services (CMS) announced Sept. 18 that all 50 states, the District of Columbia and Puerto Rico have applied to join the GENErating cost Reductions fOr US Medicaid (GENEROUS) Model, which provides most favored nation (MFN) pricing on certain prescription drugs to Medicaid programs.¹ Forty states and Puerto Rico have signed agreements, and the remaining states have until Sept. 30 to follow. Below are answers to the key questions about the GENEROUS Model.
Related to this article
With HRSA's approval window now closed, attention turns to whether health system pharmacies can reconcile rebates at scale before the pilot's Jan. 1 start.
Inside the October 2026 issue: why splitting MMR takes years, why payers cite a price that does not bind them, and what pricing rules broke.
Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.
The White House said Medicaid programs in all 50 states, D.C. and Puerto Rico now receive MFN prices, with nearly $65 billion in savings over a decade.
Rebate delays could force 340B hospitals to pay upfront and wait months for credit, distorting drug spend on the books. Valerie Bandy, PharmD, of Tecsys explains the fallout.
In this week's Pharma Pulse, PhRMA sues to block CMS's GLOBE pricing model, WFS opens a temperature-controlled cargo terminal in Lyon and Bayer commits $2.2 billion to a new Ohio manufacturing site.
In this week's Pharma Pulse, the EU Council adopts the "pharma package," Commerce details 0% tariffs for certain drugs and Sharp expands autoinjector assembly capacity.
Advertisement
Advertisement